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A mutant Shiga-like toxin IIe bound to its receptor Gb3: structure
of a group II Shiga-like toxin with altered binding specificity 
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Clifford G Clark4, James L Brunton5,6 and Randy J Read1,2,3*
Background: Shiga-like toxins (SLTs) are produced by the pathogenic strains
of Escherichia coli that cause hemorrhagic colitis and hemolytic uremic
syndrome. These diseases in humans are generally associated with group II
family members (SLT-II and SLT-IIc), whereas SLT-IIe (pig edema toxin) is
central to edema disease of swine. The pentameric B-subunit component of the
majority of family members binds to the cell-surface glycolipid globotriaosyl
ceramide (Gb3), but globotetraosyl ceramide (Gb4) is the preferred receptor for
SLT-IIe. A double-mutant of the SLT-IIe B subunit that reverses two sequence
differences from SLT-II (GT3; Gln65→Glu, Lys67→Gln, SLT-I numbering) has
been shown to bind more strongly to Gb3 than to Gb4. 
Results: To understand the molecular basis of receptor binding and specificity,
we have determined the structure of the GT3 mutant B pentamer, both in
complex with a Gb3 analogue (2.0 Å resolution; R = 0.155, Rfree = 0.194) and in
its native form (2.35 Å resolution; R = 0.187, Rfree = 0.232). 
Conclusions: These are the first structures of a member of the medically
important group II Shiga-like toxins to be reported. The structures confirm the
previous observation of multiple binding sites on each SLT monomer, although
binding site 3 is not occupied in the GT3 structure. Analysis of the binding
properties of mutants suggests that site 3 is a secondary Gb4-binding site. The
two mutated residues are located appropriately to interact with the extra
βGalNAc residue on Gb4. Differences in the binding sites provide a molecular
basis for understanding the tissue specificities and pathogenic mechanisms of
members of the SLT family. 
Introduction
In 1983 it was recognized that Shiga-like toxin-producing
Escherichia coli are associated with hemorrhagic colitis (HC)
and the hemolytic uremic syndrome (HUS) [1–3]. Since
then, an increasing number of outbreaks owing to the con-
sumption of contaminated food have been reported. In
North America, where this serious and sometimes fatal
infection is commonly called ‘hamburger disease’, E. coli
O157:H7 is the most common pathogen. In the United
States alone, approximately 20,000 people become ill and
250 people die from infection by the pathogenic strains
each year [4–6]. Shiga-like toxins (SLTs or verotoxins) are
the major virulence factors of the pathogenic E. coli strains
that cause disease in humans and animals (Table 1). Anti-
biotics have not proved useful and might even increase the
risk of complications of infection, as killing the bacteria
may accelerate the release of toxins [7,8]. Other therapies
aimed at toxin neutralization are therefore needed. 
SLTs are AB5 toxins composed of one enzymatic (A)
subunit and five copies of a cell-binding subunit (the B
pentamer). The A subunit (32 kDa) of the holotoxin is the
toxic component that acts within the target host cell. The B
pentamer (7.5 kDa × 5) is responsible for toxin attachment
to globoseries glycolipids on the cell surface [9,10]. This
attachment is required for internalization of the toxin and
retrograde routing through the Golgi apparatus to the endo-
plasmic reticulum (ER). It is thought that the A subunit
enters the cytosol at this level (reviewed in [11]), enzymati-
cally inactivates the ribosomes [12] and triggers cell death.
The glycolipid Gb3 (globotriaosyl ceramide; Figure 1) func-
tions as a receptor for SLTs and is present on the surface of
target cells, such as epithelial cells in the intestine and
endothelial cells in the kidney [13–16]. Cells without Gb3
on their surface are resistant to the toxins [9,17,18]. Gb3
expression correlates with the tissue specificity of toxin
damage and, in turn, the disease symptoms in patients [19].
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The SLTs are similar to Shiga toxin from Shigella dysente-
riae in both structure and function [20,21]. Members of the
Shiga toxin family are divided into two groups, originally
distinguished by their immunological properties (reviewed
in [22]). Group I includes Shiga toxin (ST) and SLT-I,
which differ by only one amino acid in the A subunit.
Group II includes SLT-II, SLT-IIc and SLT-IIe, which
are very similar to each other in sequence but significantly
different from SLT-I (Figure 2). All family members
except SLT-IIe are associated with HC and HUS in
humans [1,23,24]. SLT-IIe, or pig edema toxin, is associ-
ated with edema disease of swine, which is characterized
by microvascular damage causing edema in the subcuta-
neous tissue of the eye lids, the central nervous system,
and the spiral colon [25]. This disease is an important
cause of death associated with weaning in swine herds in
parts of Europe. 
E. coli strains producing SLT-II have been associated with
more severe disease in humans than those strains which
produce SLT-I [18,26–28]. As there is no detectable dif-
ference in enzymatic activity of the A subunits, this obser-
vation has been ascribed to differences in receptor
binding. Indeed, A–B hybrid toxins of SLT-I and SLT-II
demonstrate that cytotoxicity is modulated by the B sub-
units [29]. The binding affinity of SLT-I for Gb3-bearing
target cells (Kd = 4.6 × 10–8 M) is higher than that of group
II toxins (Kd = 3.7 × 10–7 M) [29,26]. It has been proposed
that SLT-II’s lower receptor-binding affinity enables it to
stay longer in the circulation and to reach the kidneys
more easily than SLT-I [27,26]. Furthermore, SLT-II has
been shown to be much more cytotoxic than SLT-I
towards kidney microvascular endothelial cells in vivo
[26,28]. The B subunits are an ideal target for rational drug
design, because binding to the cell surface is a crucial step
in cytotoxicity. A new drug (Synsorb-Pk), derived from
the glycolipid analogue Pk-MCO (Figure 1), is being
tested against HUS in children infected with O157:H7
E. coli [30,31]. It is proposed that Synsorb-Pk should
adsorb toxins in the intestinal lumen, preventing them
from entering the tissues and circulatory system.
Synsorb-Pk is presently in phase III clinical trials. Phase
II trials showed a trend towards protection against HUS;
however, this did not achieve statistical significance
because the study did not enrol sufficient patients with
proven E. coli O157:H7 infection [32]. We hope to find
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Table 1
The Shiga toxin family*.
Toxin Alternative names Binding specificity Disease caused Crystal structures No. of sugars bound 
ST Shiga toxin Gb3 Dysentery Holotoxin† (– sugar) –‡
SLT-I Shiga-like toxin I, verotoxin 1 Gb3 Human HC and HUS B Pentamer§ (+ sugar) Three per monomer
B Pentamer# (– sugar) –
SLT-II Shiga-like toxin II, verotoxin 2 Gb3 Human HC and HUS None –
SLT-IIc Shiga-like toxin IIc, verotoxin 2c Gb3 Human HC and HUS None –
SLT-IIe Shiga-like toxin IIe, pig edema toxin, Gb4 Edema disease of swine None –
verotoxin 2v Gb3¶
GT3 Q65E/K67Q mutant of SLT-Ile Gb3 SLT-I-like disease in pigs B Pentamer¥ (+ sugar) Two per monomer
*Reviewed in [22]. †[41]. ‡The Shiga toxin B subunit is identical to the SLT-I B subunit and should have the same three distinct receptor-binding
sites as SLT-I B. §[37]. #[40]. ¶Binding affinity for Gb3 is significantly lower than for Gb4. ¥This study.
Figure 1
Cell surface receptors and the Gb3 analogue. (a) Gb3 (b) Gb4 and
(c) the Gb3 analogue 8-methoxycarbonyloctyl trisaccharide (Pk-MCO).
The Pk trisaccharide terminus is the same as the carbohydrate portion
of the glycolipid Gb3 (Gal(α1–4)Gal(β1–4)Glc(β1–8) ceramide) that is
recognized by the B pentamer of SLTs. In this paper, we refer to this
trisaccharide as Pk, and to the three sugar residues αGal, βGal and
βGlc as Gal1, Gal2 and Glc, respectively.
st8302.qxd  03/22/2000  11:19  Page 254
higher affinity inhibitors through close examination of
atomic-level interactions between the B pentamers and
their receptors. 
All of the SLTs associated with diseases in humans bind
to Gb3. Although the SLT-IIe B subunit shares 62%
amino acid sequence identity with SLT-I B and 87%
identity with SLT-II B, it binds the glycolipid Gb4
(globotetraosyl ceramide; Figure 1) in preference to Gb3
[33]. Cells bearing only Gb3 are still susceptible to the
action of SLT-IIe, but not as susceptible as those bearing
Gb4 [34]. To explore which amino acids determine
binding specificity, Tyrrell et al. [35] constructed a series
of SLT-IIe mutants by substituting residues from the
SLT-II B sequence. One double-mutant of the SLT-IIe B
subunit (Gln65→Glu, Lys67→Gln, designated GT3;
residues numbered according to the alignment with SLT-I
B in Figure 2) changes its binding preference from Gb4 to
Gb3 [35]. The change in preference occurs through the
combination of a dramatic reduction in binding to Gb4 and
an increase in binding to Gb3. Moreover, GT3 causes an
SLT-I-like disease in pigs [36], thus providing strong evi-
dence that the binding specificity dominates the cytotoxic
tissue specificity in vivo.
Previously, we studied the binding of Gb3 to a group I
SLT by determining the structure of SLT-I B in complex
with a Gb3 analogue [37]. Three distinct Gb3 receptor
binding sites are present in each SLT-I B monomer. The
study of group II B subunits has been hindered by the dif-
ficulty of expressing large amounts in a biologically active
form [38]. In this study, we report the first group II SLT
structures: the GT3 mutant B pentamer in complex with
the Gb3 analogue Pk-MCO (Figure 1) at 2.0 Å resolution
and the native GT3 structure at 2.35 Å resolution. The
GT3 B subunit differs from the SLT-II B subunit in only
seven of 68 common positions and is thus an excellent
model for other group II toxins. Having the structure of
this SLT-II group member allows comparisons with the
SLT-I structure and sheds light on the relative receptor-
binding activities of the group I and II B subunits.
Results and discussion
Quality of the structures
The molecular replacement solution of the GT3–Pk-MCO
complex was determined first and revealed one GT3 B
pentamer per asymmetric unit. Crystallographic refine-
ment of the complex with all data from 31.0–2.0 Å pro-
duced a residual R factor of 0.155 (Rfree = 0.194; see
Table 2). The final refined model of the structure
includes all 340 amino acid residues of the B pentamer,
seven carbohydrate moieties of Pk-MCO molecules and
160 water molecules. Excellent electron density is
observed for the entire GT3 B pentamer, whereas the
quality of density for carbohydrates varies in different
binding sites (Table 3; Figure 3), as discussed below.
An analysis of protein stereochemistry with the program
PROCHECK [39] indicates that, for all tested properties,
the model geometry is equal to or better than that
expected for a 2.0 Å structure (data not shown).
A Ramachandran plot indicates that over 95% of non-
glycine residues are in the most favoured regions and the
remainder are in additional allowed regions. The root
mean square deviation (rmsd) among the five B monomers
is low (0.15 Å for all Cα atoms and 0.23 Å for all non-hydro-
gen protein atoms), although a very loose noncrystallo-
graphic symmetry (NCS) restraint (wncs = 10 kcal mol–1 Å–2)
was used in the final refinement.
The molecular replacement solution of native GT3
revealed four GT3 B pentamers per asymmetric unit. All
data from 21.0–2.35 Å were used in the crystallographic
refinement, producing a working R factor of 0.187 and an
Rfree of 0.232. The model contains coordinates for all
1360 amino acids of the four B pentamers, and 359 water
molecules. Over 94% of the non-glycine residues are in
the most favored region of the Ramachandran plot as
defined by PROCHECK [39]. As with the structure of
the complex, the rmsds among the 20 B monomers are
low (0.17 Å for all Cα and 0.59 Å for all non-hydrogen
protein atoms). Most of the deviations arise from the
differing conformations of Trp34 in the monomers,
discussed below.
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Figure 2
Alignment of the amino acid sequences of
B subunits of SLTs. GT3 is a mutated form of
SLT-IIe. Invariant residues are shown boxed.
Asterisks denote residues involved in sugar
binding and filled triangles denote the two
residues of GT3 that were mutated to be the
same as those in SLT-II. Secondary structure
elements are indicated by broad arrows
(β strands) and a cylinder (α helix). The
B subunit of Shiga toxin from Shigella
dysenteriae is identical to that of SLT-I. (This
figure was generated with the program
ALSCRIPT [71].)
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Structure of GT3
The GT3 B subunit has a typical oligomer-binding (OB)
fold that consists of a six-stranded antiparallel β barrel
capped by an α helix [40]. Each GT3 B subunit monomer
contains 68 residues (numbered 2–69, Figure 2), one
residue fewer than the SLT-I B monomer [35]. A disul-
phide bond formed between Cys4 and Cys57 of GT3 is
also present in SLT-I B. The two mutant residues of GT3
are located in strand β6 near the C terminus, at the inter-
face between neighbouring monomers (Figure 4a). 
Carbohydrate binding has little effect on the conformation
of the GT3 B subunit monomer: the average rmsd for com-
parisons of Cα atoms in monomers of complexed and
uncomplexed GT3 is approximately 0.2 Å. Furthermore,
the average rmsd for similar comparisons of GT3 monomers
(complexed or uncomplexed) with SLT-I monomers (com-
plexed or uncomplexed) is approximately 0.5 Å. The small
difference between the GT3 and SLT-I monomers is not
surprising, as the molecules share 63% sequence identity. 
Larger differences emerge when quaternary structures are
compared. In the native SLT-I B pentamer [40] there is a
screw component to the fivefold symmetry with a transla-
tion of 1.3 Å parallel to the fivefold axis — the structure,
therefore, resembles a lock–washer. In contrast, no signifi-
cant screw component is seen in the GT3–Pk-MCO
complex, the SLT-I–Pk-MCO complex [37] or the ST
holotoxin [41], and the rotation angles between neighbour-
ing monomers are characteristic of good fivefold symmetry.
The native GT3 pentamers, in general, show greater devia-
tions from perfect fivefold symmetry, although they do not
have a lock–washer structure. The analysis of deviations
from perfect fivefold symmetry, summarized in Table 4,
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Table 3
Quality of the electron density and extent of the carbohydrate
model for each binding site in the GT3–Pk-MCO complex.
Monomer Binding site Density quality Sugar molecule
modelled
B1 Site 1 Poor, discontinuous Gal1–Gal2–Glc
Site 2 Excellent Gal1–Gal2–Glc–tail*
B2 Site 1 Poor, discontinuous Gal1–Gal2
Site 2 Excellent Gal1–Gal2–Glc
B3 Site 1 No density None
Site 2 Excellent Gal1–Gal2–Glc–tail*
B4 Site 1 Very little density None
Site 2 No density None
B5 Site 1 Poor, discontinuous Gal1–Gal2
Site 2 Excellent Gal1–Gal2–Glc–tail*
*Only part of the MCO tail (3–4 carbon atom chain) was built
and refined.
Table 2
Crystallographic data.
Structure GT3–Pk-MCO complex GT3 native
Space group P212121 P21
Unit cell
a, b, c (Å) 62.3, 78.9, 78.8 113.5, 54.5, 116.9
β (°) 109.1
No. unique reflections 25,704 (31.0–2.0 Å) 34,187 (21.0–2.35 Å)
No. measurements 308,496 62,524
Rmerge*
Overall (%) 10.2 (31.0–2.00 Å) 8.4 (21.0–2.35 Å)
Highest resolution shell (%) 22.2 (2.15–2.00 Å) 33.0 (2.49–2.35 Å)
Completeness of data
Overall (%) 95.3 (∞–2.00 Å) 60.4 (∞–2.35 Å)
Highest resolution shell (%) 87.2 (2.15–2.00 Å) 12.3 (2.39–2.35 Å)
Model
Protein (non-hydrogen atoms) 2665 10,660
Carbohydrate (non-hydrogen atoms) 228 N/A
Solvent (water molecules) 160 359
Average B factor (Å2)
Protein 19.5 28.9
Carbohydrate 41.7 N/A
Solvent 33.8 31.4
R factor† (working data) 0.155 (31.0–2.00 Å) 0.187 (21.0–2.35 Å)
Rfree‡ 0.194 (2541 reflections) 0.232 (1055 reflections)
Rmsd bond lengths (Å) 0.015 0.012
Rmsd bond angles (°) 1.6 1.7
*Rmerge = Σ |Ii – <Ii>| / Σ |I|, where I is the intensity of the reflections. †R factor = Σ|Fo–Fc| / ΣFo, where Fo is the observed structure-factor amplitude
from diffraction data and Fc is the calculated structure-factor amplitude from the molecular model. ‡Rfree is calculated as for the R factor, using only
an unrefined subset of the diffraction data [61].
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provides more evidence for the hypothesis that interactions
with a ligand or an A subunit enforce a closer to perfect
fivefold symmetry on the B pentamer. It has been specu-
lated that reduced stability of the pentamer interactions in
the absence of the A subunit could be relevant to toxin
assembly (WGJ Hol, personal communication).
Most amino acid sidechains in the structures exhibit a
single, well-defined conformation. The sidechains of
residue Glu10 of each monomer show two alternative con-
formations in the complex structure at 2.0 Å resolution.
Both the SigmaA-weighted 2Fo–Fc map [42,43] and five-
fold-averaged electron density accommodate the two alter-
native sidechain models. Although there are indications of
similar static disorder in the native structure, the resolution
was not considered sufficient to model two conformations. 
An interesting example of multiple conformations is seen
for the Trp34 sidechain. Collectively, the crystal struc-
tures of SLT B subunits indicate that this sidechain is
intrinsically flexible. When exposed to solvent, as in the
ST holotoxin structure [41] or in four of the five
monomers of the GT3–Pk-MCO complex, this tryptophan
sidechain lacks clear electron density. Disordered Trp34
sidechains are also observed in other SLT structures
where the indole rings lack specific interactions (HL and
RJR, unpublished observations). Trp34 is only well-
ordered when involved in interactions that select one of its
possible conformations; and a variety of conformers is
seen. For example, in the native SLT-I B crystal struc-
ture, the screw translation along the fivefold axis allows
four of the indole rings to interact with one another and to
maintain a common well-defined conformation. In the
SLT-I–Pk-MCO complex the Trp34 indole ring stacks
against the β-galactose ring of Gb3 in site 3, and there is
clear density for what would otherwise be an unfavourable
sidechain conformation [37]. In the native GT3 structure,
many of the Trp34 sidechains from neighbouring pen-
tamers stack against each other. In addition, because of
the deviations from perfect fivefold symmetry, a number
of other Trp34 sidechains stack in the manner seen in the
native SLT-I B structure.
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Figure 3
Typical electron-density maps for Pk-MCO. Pk-MCO is shown in ball-
and-stick representation with carbon atoms in yellow and oxygen
atoms in red. Electron density is shown for Pk-MCO bound to (a) site
1 (monomer B1) and (b) site 2 (monomer B1). Electron-density maps
are contoured at 1.0 × root mean square electron density, prepared
with the program O [59].
Figure 4
Two orthogonal views of the GT3 B pentamer bound to Pk-MCO.
Each monomer is shown in a different colour. (a) View along the
fivefold axis. The sugar-receptor binding surface is towards the viewer,
corresponding to the bottom surface in (b). There is no sugar binding
at site 3 in this structure. Trp34 sidechains in site 3 are shown in ball-
and-stick representation. (b) Side view. The N and C termini of the two
monomers in colour are labelled. The top face of the B pentamer is the
interface associated with the A subunit of the holotoxin; the bottom
face of the B pentamer is the receptor-binding surface. Sugars bound
at site 1 of each monomer are shown in green and sugars bound at
site 2 are in purple. The mutated residues Glu65 and Gln67 are shown
in ball-and-stick representation for one subunit. (These figures were
generated with the program MOLSCRIPT [72].)
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Pk-MCO trisaccharide binding
The OB-fold has been found in several proteins that bind
oligosaccharides or oligonucleotides (reviewed in [44]).
All these proteins have a single binding site in a struc-
turally conserved location. In our previous study of 
the SLT-I–Pk-MCO complex, however, three distinct
binding sites were found in each SLT-I B subunit (i.e., 15
binding sites per B pentamer [37]). Site 2 (Figure 4b) is
topologically equivalent to the binding sites found in
other OB-fold proteins, whereas site 1 corresponds to a
previously predicted binding site [40]. In this study, two
binding sites have been found in the GT3–Pk-MCO
complex: sites 1 and 2 (Table 3; Figures 4 and 5). The
conformations of the bound trisaccharides are similar to
those in the  SLT-I–Pk-MCO complex. The presence of
all trisaccharides on the flat surface opposite to the A
subunit confirms this region as the membrane-binding
surface. As discussed previously for the SLT-I B structure
[37], the different orientations of the Gb3 trisaccharide in
the distinct binding sites of the B subunits would allow
the sugar–lipid linkers to adopt favourable conformations
when the toxin binds to the host cell membrane.
Electron density is visible for sugar residues at the major-
ity of binding sites. The quality of the density varies
between sites 1 and 2 as well as between equivalent sites
related by NCS (Table 3; Figure 3, in Table 3 and
throughout the rest of the paper we will refer to the B sub-
units from the GT3–Pk-MCO complex as B1–B5). This
variation in quality suggests that the isolated Pk-MCO
binds more tightly to site 2 than to site 1. A similar varia-
tion among sites was observed in the structure of the
SLT-I–Pk-MCO complex. Furthermore, a nuclear mag-
netic resonance (NMR) study of trisaccharide binding to
the SLT-I B subunit showed that, at a 1:1 ratio of carbohy-
drate to protein, binding was seen only at site 2 [45]. This
indicates that site 2 has the highest affinity for the isolated
carbohydrate. It is important, however, to note that pre-
sentation of the trisaccharide by a glycolipid embedded in
a membrane could well change the relative affinities. For
the binding sites related by NCS, the differences appear
to be mainly due to packing environments that are not
crystallographically equivalent. With the exception of site
2 of B4, crystal-packing contacts do not block sugar access
to any binding sites.
There are no direct interactions between the trisaccha-
rides in the different binding sites of the pentamer. The
binding sites are constructed from residues of two adja-
cent monomers and thus require the pentameric assem-
bly of the B pentamer (Figure 5). The trisaccharides sit
in shallow clefts on the relatively flat sugar-binding
surface. Site 1 is located in a cleft near the interface with
an adjacent B monomer, whereas site 2 is in an elongated
shallow cleft along the flat surface (Figure 4a). The
residues involved in sugar binding are either conserved
in the Shiga toxin family or are conservatively substi-
tuted (Figure 2).
Binding at site 1
Electron density for the Pk-MCO trisaccharide at site 1 is
visible, with varying quality, in four of the five B monomers
of the GT3 pentamer (Table 3). In some cases, electron
density reveals only the two terminal galactose residues,
which make the primary interactions with the protein.
Clear density for a trisaccharide is seen in monomer B1,
and the interactions described below are based primarily on
this binding site.
The interactions in site 1 (see Figure 5a) are very similar
to those already described for the closely related binding
site 1 in SLT-I [37]. Hydrophobic interactions are domi-
nated by the aromatic ring of Trp30, which stacks against
the B-face of Gal2 as also observed for Phe30 in the struc-
ture of SLT-I–Pk-MCO [37]. One additional interaction is
observed: a hydrogen bond from Lys13 to O3 of Gal1
(Figure 5a). The substantial increase in resolution,
however, allows us to observe the role of solvent, as in the
water-mediated hydrogen bond from Glu28 to Gal1
(Figure 5a). With few exceptions, the site 1 contact
residues are conserved in the SLTs. Trp30 is a conserva-
tive substitution for Phe30 in SLT-I, and only the 
mainchain of Tyr29 (leucine in SLT-I) contacts the sugar
(Figure 5a). In SLT-IIc, however, the charged Asp17
residue (Figure 5a) is replaced by a neutral asparagine
(Figure 2), resulting in a weaker hydrogen bond. This
would correlate with the reduced cytoxicity of this toxin
variant and mutants of SLT-II [46]. Site-directed mutage-
nesis has shown that the conserved residue Gly60 is essen-
tial for cytotoxicity of SLT-I and SLT-II [47]. Gly60 is a
binding residue in site 1 of both SLT-I B and GT3. It
adopts a mainchain conformation (φ ≈ 90°, ψ ≈ 0°) that is
inaccessible to non-glycine residues; substitution of this
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Table 4
Deviations of GT3 B subunit pentamers from perfect fivefold
noncrystallographic symmetry.
Pentamer Rotation angles* (º) Screw translations* (Å)
range† rmsd‡ range† rmsd‡
GT3–Pk-MCO 71.23–72.77 0.70 –0.73–0.92 0.60
GT3 native 1 69.68–74.70 2.08 –0.63–1.27 0.66
GT3 native 2 69.60–74.84 2.07 –0.24–0.25 0.17
GT3 native 3 71.37–72.70 0.58 –1.05–1.90 1.07
GT3 native 4 70.70–72.93 0.77 –0.84–1.69 0.91
*Rotation angles and screw translations refer to the noncrystallographic
symmetry (NCS) operation required to superimpose one monomer on
its neighbour in a pentamer. †The range of an angle or translation refers
to the extreme values seen for that pentamer. ‡The rmsd statistics refer
to deviations from the values expected for a pentamer with perfect
fivefold symmetry: 72º for angles and zero for translations.
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residue would alter the conformation of the β5–β6 loop,
which is involved not only in site 1 but also in site 2. 
Binding at site 2
Four B monomers have clear electron density for 
Pk-MCO in site 2 (Table 3), defining the entire Pk-MCO
trisaccharide and part of its hydrophobic tail (Figure 3b).
Binding at site 2 of B4 is blocked by crystal packing. The
trisaccharide is oriented approximately parallel to the
protein surface (Figure 4), allowing all three sugar residues
to interact directly with the protein. This extensive inter-
action probably explains the strong density observed at site
2, which is similar to that observed for the SLT-I–Pk-MCO
complex. Hydrogen bonds with Gal1 dominate the
binding interactions (Figure 5b). Five water molecules
mediate hydrogen bonding between the protein and sugar
molecule at site 2. The majority of the residues in site 2
are conserved and play a similar role to those in the 
SLT-I–Pk-MCO complex. One exception is the substitu-
tion of Glu16 for aspartic acid in SLT-I B, where the
water-mediated hydrogen bond seen for Glu16
(Figure 5b) is replaced by a direct interaction for Asp16.
This substitution might be responsible in part for the
reduced Gb3 affinity of the group II toxins. 
Site-directed mutagenesis has shown that Arg33 plays an
important role in the cytotoxicity of SLT-I and SLT-II
[47]. The results can be explained by the extensive
involvement of its sidechain in hydrogen bonding to the
terminal galactose of Gb3 trisaccharides in site 2 of both
SLT-I [37] and GT3. By analogy, Arg33 should play a
similar role in SLT-II. Mutations of Arg33 could influence
binding activity indirectly, however, as its sidechain is also
extensively involved in interactions that stabilize the ter-
tiary structure of the toxin pentamer.
Lack of Pk-MCO binding at site 3
In the SLT-I–Pk-MCO complex, the trisaccharide chain
at site 3 is nearly perpendicular to the protein surface
and therefore has fewer contacts with the protein than
the two  other binding sites [37]. Nonetheless, good elec-
tron density for the trisaccharide is clearly observed in all
20 equivalent binding sites over the four pentamers in
the asymmetric unit of the SLT-I–Pk-MCO complex.
This binding is also observed in a Gly62→Thr mutant of
SLT-I B in a different crystal form (HL and RJR,
unpublished observations), which provides further evi-
dence that binding in site 3 of SLT-I is not a crystalliza-
tion artifact. 
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Figure 5
Stereo diagrams of the Pk-MCO-binding sites
in a GT3 B subunit. Protein segments are
drawn with open bonds and the
oligosaccharide with filled bonds. Dashed
lines indicate intermolecular hydrogen bonds;
asterisks indicate amino acid residues from
an adjacent B subunit of the pentamer. Water
molecules are depicted as large filled circles.
(a) The Pk-MCO trisaccharide at site 1.
(b) The Pk-MCO trisaccharide at site 2.
(The figure was generated using the program
MOLSCRIPT [72].)
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The lack of binding in site 3 of GT3 was unexpected, as
changes in this region are minimal. All but one of the
residues surrounding the site are conserved from SLT-I,
with the sole exception being the substitution of Asn18 for
Asp18; as discussed below, residue 18 has been implicated
in discriminating between Gb3 and Gb4. Apart from the
exposed Trp34 sidechains, none of the residues in the
binding site differ significantly in conformation. Unless
more distant differences have subtle effects on solvent
structure, the substitution of an amide for a carboxylate in
residue 18 must be responsible for the reduction in affin-
ity for the Gb3 trisaccharide. In the SLT-I–Pk-MCO
complex, Asp18 accepts a bifurcated hydrogen bond from
O4 of Gal1. Asn18, on the other hand, must either donate
or accept a single hydrogen bond. The lack of observed
binding, however, does not necessarily imply that Gb3
fails to bind in site 3, but may only indicate that the con-
centration of Pk-MCO was too low. Even in the other,
presumably stronger, binding sites, a 50 mM concentra-
tion of Pk-MCO is not sufficient to compete with crystal-
packing interactions and provide universal occupation. It
should also be noted, that in earlier attempts to cocrystal-
lize the related SLT-I B subunit and Pk-MCO, no carbo-
hydrate binding was observed until the carbohydrate
concentration was raised above 20 mM (HL and RJR,
unpublished observations); this implies that the level of
saturation at 50mM will be low at all sites and that the
observation of binding will be very sensitive to minor
reductions in affinity.
Correlation with binding data for carbohydrate analogues
Nyholm et al. [48] have tested the binding of various deoxy
analogues of Gb3 to several members of the Shiga toxin
family. As discussed previously, the results for SLT-I are
consistent with the observed binding interactions, with the
exception being that no direct interactions with the 2′-OH
of Gal2 were observed to explain the importance of this
moiety in recognition [37]. We had speculated that there
might be water-mediated interactions, which are now seen
to exist in site 2 of the GT3 mutant complex (Figure 5b). 
In general, as expected from the similarity of observed
binding interactions, the same hydroxyl groups are impor-
tant for binding to all of the toxins studied [48]. SLT-I
and SLT-IIe differ significantly only for Gal1–3′-deoxy,
which eliminates binding in SLT-IIe but has little effect
in SLT-I. This hydroxyl group makes a direct hydrogen
bond to SLT-I only in site 2, whereas in GT3 (and pre-
sumably also in SLT-IIe and SLT-II) it interacts with
Lys13 in site 1. Detailed analysis is complicated, however,
by the possibility that the relative affinities of the multiple
binding sites could differ among family members. For
example, SLT-I binding might also be less affected by
Gal1–3′-deoxy because site 3, which does not interact with
this hydroxyl group [37], plays a more important role in
Gb3 binding than it does in SLT-IIe.
In the same study [48], computer models for the binding
of the Gb3 trisaccharide in sites 1 and 2 were presented. As
discussed previously, the general location of the predicted
binding sites agrees with the experimental results, but the
details of the interactions are quite different [37]. Subse-
quent NMR experiments have confirmed the experimen-
tally observed orientation of soluble trisaccharide in
binding site 2 [45]. The results of fluorescence-resonance
energy-transfer experiments have been suggested to be
more consistent with the computer model for site 2 than
the experimental binding results [49]. However, the dif-
ferences in predicted distances are small; given experi-
mental errors in the calibration of distances and, more
importantly, uncertainty in the position of the fluorescent
probe at the end of a flexible linker to the glucose residue,
the energy-transfer results are also consistent with the
experimentally observed ligand positions. 
Mutations and binding specificity
Our structure reveals that the two mutated residues
(Gln65→Glu and Lys67→Gln) are both associated with
site 1 (Figure 5a) and that one (Gln65→Glu) is also in the
vicinity of site 2 (Figure 5b). Neither single mutation can
change the binding preference of SLT-IIe from Gb4 to
Gb3 [35], indicating that each of the two residues makes a
significant contribution to the preference for Gb4 over
Gb3. The location of the mutations and the strength of
their effect also suggests that Gb4 binds most strongly to
site 1 of SLT-IIe. Possible binding interactions for Gb4 at
this site of SLT-IIe have been proposed in our previous
modelling paper [50], showing that direct interactions
could be made between the βGalNAc moiety and Gln65
and Lys67. (Subsequent refinement of the GT3 complex
structure has not shown any significant differences in the
interactions with Pk-MCO, which formed the scaffold for
the Gb4 model.) The two mutations might also affect the
orientation of the sidechains of Asn15 and Lys13. GT3 has
the same binding residues in site 1 as SLT-II, and there-
fore Gb3 binding to SLT-II in this site can be inferred to
be the same (Figure 5a).
The two GT3 mutations reverse the only sequence differ-
ences in binding site 1 between SLT-IIe and SLT-II, with
a dramatic reduction of Gb4 binding and a slight increase in
Gb3 binding. In contrast to SLT-II, however, which does
not bind Gb4, GT3 still retains some Gb4 binding [35], pre-
sumably in one or both of sites 2 and 3. There is room for
the extra βGalNAc residue of Gb4, as seen by placing low-
energy conformations of Gb4 [50] into these sites (results
not shown). It is interesting to consider whether the
remaining sequence differences shed light on possible Gb4
binding in sites 2 and 3. In total, the B subunit of SLT-IIe
differs from that of SLT-II in 11 positions (Figure 2),
including a C-terminal deletion of two residues. Nine
sequence differences remain in GT3; of these, seven are
situated far from any of the binding sites and would not be
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expected to contribute to any difference in binding speci-
ficity. Thus, this leaves only two binding site residues that
differ between GT3 and SLT-II — at positions 18 and 32.
The Gb4 superpositions show that Asn32 (serine in SLT-II)
could interact with the βGalNAc residue of a Gb4 molecule
bound to site 2. This residue, however, is also an
asparagine in SLT-I, which binds exclusively to Gb3, and
therefore the presence of Asn32 cannot be pivotal to speci-
ficity. The sole remaining residue is Asn18, which is an
aspartate in both SLT-I and SLT-II. Interestingly, a muta-
tion of Asp18 to asparagine in SLT-I confers Gb4-binding
activity [35]. As discussed above, the interactions of an
asparagine with Gb3 in site 3 would not be quite as
favourable as the interaction of an aspartate. On the other
hand, the Gb4 superpositions show that an asparagine in
this position could interact with the βGalNAc residue of
Gb4 bound to site 3. It seems likely, therefore, that site 3 is
a secondary Gb4-binding site in SLT-IIe.
Implications for Gb3 binding to SLT-II
SLT-II binds to Gb3 less avidly than SLT-I, which may
be relevant to SLT-II’s association with human disease
[27,26]. As discussed above, the substitution of Asp16 in
SLT-I with a glutamate in both SLT-II and GT3 may be
responsible in part for the reduced binding affinity. In
addition, SLT-II differs from SLT-I in ways that are not
shared with GT3 (or SLT-IIe). Figure 2 shows that SLT-II
is unique in the substitution of two serine residues for
asparagines, at positions 32 and 55, that are involved in
binding at site 2. These substitutions will change the
nature and possibly the strength of interactions in this
binding site.
Biological implications
In foodborne infections caused by Escherichia coli
O157:H7 the Shiga-like toxins (SLTs) are thought to be
responsible for life-threatening vascular complications,
such as the hemolytic uremic syndrome (HUS). The
SLTs associated with disease in humans can be divided
into group I and II members. Previous studies have
focused on the group I toxin SLT-I, partly because of
difficulties in producing sufficient quantities of the recep-
tor-binding B subunit of group II toxins. The group II
toxins SLT-II and SLT-IIc, however, appear to be asso-
ciated with more severe cases of disease. A variety of
studies have shown that cytotoxicity, tissue specificity
and pathology are determined by the B subunit and its
properties in binding to the glycolipid receptor Gb3. One
important determinant may be the lower receptor-
binding affinity exhibited by the group II toxins, which
has been speculated to allow the more widespread dis-
semination of these toxins in the body.
The group II toxins include SLT-IIe, which is associ-
ated with edema disease of swine and differs from other
SLTs by binding to Gb4 in preference to Gb3. A double-
mutant of the SLT-IIe B subunit, designated GT3,
reverses two sequence differences from SLT-II and
switches the binding preference to Gb3. We report here a
structural study of the binding of a Gb3 analogue to
GT3. The study was carried out not only to provide a
molecular explanation for the change of specificity, but
also to obtain the first structural insights into the group
II SLTs.
The results from this structure and our previous study
on SLT-I [37] indicate the existence of multiple recep-
tor- binding sites in SLTs. The structures provide a mol-
ecular basis for the differences in binding affinity in
vitro, which are essential to understanding the tissue
specificities of the two SLT groups in vivo and the path-
ogenic mechanisms of the disease. Finally, the receptor-
binding sites revealed in these structures are excellent
targets for drug design and vaccine development.
Materials and methods
GT3 B subunit overproducing clone
The B subunit encoding the sequence of pGT3 [35] was amplified by
the polymerase chain reaction using the primers 5′-ATAGAATTCGT-
GAATGAAAGG-3′ for + strand synthesis and 5′-TGCAAGCTTAAA-
CAAAAGACGCGC-3′ for — strand synthesis [51]. The former primer
consists of an EcoRI recognition sequence followed by residues
1156–1167 of the vte sequence [52] (Genbank accession number
M36727); while the latter primer consists of a HindIII recognition
sequence followed by residues 1473–1459 of the — strand of the vte
sequence. The resulting amplicon was cleaved with EcoRI and HindIII,
gel purified, and ligated to the EcoRI and HindIII sites of the expression
vector pKK223-3 [53]. The construct was transformed into the host
strain E. coli JM101, ∆ lac pro sup E thi (F′ traD36 lacZ ∆ M15 proAB
lacIq) and the sequence of the B subunit cistron was confirmed. The
plasmid was designated pGT3B.
Expression and purification of the GT3 B subunit
Strain JM101 (pGT3B) was grown in Luria broth supplemented with
carbenicillin 50 µg ml–1 to mid-exponential phase (A600 = 0.6). B
subunit production was then induced with isopropyl β-D-thiogalactoside
(2 mM) and incubation was continued for 4 h with aeration. Periplasmic
extracts were prepared in phosphate-buffered saline (PBS) containing
0.1mg ml–1 polymyxin B, as described previously [54]. The extract was
concentrated by ultrafiltration using an Amicon YM10 membrane, and
dialyzed against 50 mM Tris pH 8.0. Chromatography on Q sepharose
(Pharmacia) in 50 mM Tris pH 8.0 yielded virtually pure B subunit in the
flow-through fractions. These fractions were pooled and dialyzed
against 25 mM ethanolamine HCl pH 9.4 and the material was applied
to a chromatofocusing column of polybuffer exchanger 94 (Pharmacia).
GT3 B subunit was eluted (at pH 8.5) using polybuffer 96 pH 7.0. The
ampholytes were removed by gel filtration on Sephadex G-50 and the
purified B subunit was lyophilized from solution in 50 mM NH4CO3.
Crystallization and data collection
The GT3–Pk-MCO complex was crystallized by the hanging-drop
vapour diffusion technique. The hanging drops were formed by mixing
3 µl of the GT3–Pk-MCO complex (5 mg ml–1 GT3 + 50 mM Pk-MCO)
with 3 µl well solution (1 M NaCl, 10 mM Tris-HCl pH 8.4). Crystals
grew to a typical size of 0.3 × 0.4 × 0.6 mm3 and diffracted to 2.0 Å
resolution. Data were collected at room temperature using a Siemens
multiwire area detector and were processed with XENGEN 2.0 [55]. 
GT3 native crystals were grown with a well solution containing 8%
polyethylene glycol (PEG) 8000, 0.1 M NaCl and 0.1 M imidazole
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(pH 7.4) using the hanging-drop vapour diffusion method. The hanging
drops were formed with equal volumes of well solution and protein
solution (10 mg ml–1). Data to 2.35 Å resolution were collected at room
temperature using a Siemens multiwire area detector and were
processed with XENGEN 2.0 [55]. Unlike the data for the complex,
these data were weak and relatively incomplete (Table 2).
Structure determination of the GT3–Pk-MCO complex
The GT3–Pk-MCO structure was solved by molecular replacement
using the SLT-I B pentamer from the SLT-I–Pk-MCO complex [37] as
the search model. The orientation of the search model was determined
with the AMoRe package [56]. Ten equal weight peaks related by 
fivefold NCS and twofold crystallographic symmetry had the highest
correlation coefficient in the rotation search (r = 0.31, 8.0–4.0 Å), twice
as high as the highest noise peak. The search model in the averaged
orientation derived from the top ten rotation peaks was used in a trans-
lation search with the program BRUTE [57]. The translation search
gave a correlation coefficient of 0.60 for the best solution. 
Refinement calculations were carried out with X-PLOR [58] and manual
rebuilding with O [59]. Electron-density maps used for model rebuilding
were improved by fivefold NCS averaging and solvent flattening with the
DEMON package [60]. At all stages, the introduction of new degrees of
freedom was validated with Rfree [61]. Following initial rigid-body refine-
ment, non-conserved residues were substituted and the model was
adjusted manually. Further rigid-body refinement was followed by posi-
tional refinement by energy minimization, maintaining strict fivefold NCS.
The model was then subjected to simulated annealing to remove the
remaining bias from the initial model. Further refinement used NCS
restraints instead of constraints, initially with a relatively tight NCS weight
of 300 kcal mol–1 Å–2. In the course of the refinement the Gb3 trisaccha-
rides and water molecules were incorporated into the model and the
strength of the NCS restraint was gradually reduced to 10 kcal mol–1
Å–2. The relaxation of the NCS restraint improved both the R factor and
Rfree. At this stage, individual temperature factors (B factors) were
refined with a restraint of σ = 1.5 Å2 for NCS-related atoms and tight
restraints of 0.25 Å2 for mainchain atoms and 0.5 Å2 for sidechain
atoms. In the final stage, a bulk-solvent correction [62] was applied in
refinement against the MLF maximum-likelihood refinement target [63].
The final R factor is 0.155 for all data in the range 31.0–2.0 Å, and Rfree
is 0.194 (Table 2). The presence of fivefold NCS in the crystal will
reduce the difference between R and Rfree because correlations
between NCS-related reflections will cause overfitting to propagate to a
certain extent into the cross-validation data. Nonetheless, numerical
experiments indicate that Rfree is still a useful indicator of the validity of a
refinement process in the presence of NCS [64].
Structure determination of native GT3
The unit-cell volume was judged sufficient to contain four pentamers, with
a Matthews’ coefficient [65] of 2.25 Å3 Da–1. A rotation function using
the complexed GT3 model described above was computed in AMoRe
[56] from the CCP4 suite [66] using data from 5–10 Å resolution. This
yielded ten equivalent peaks at about four times the rmsd above the
mean (with the next highest peaks at 2 × rms), corresponding to two
unique solutions to the orientation problem. A solution to the translation
function, however, could not be found for either rotation function solution.
The pentamer models were improved by expanding the data to space
group P1 and carrying out rigid-body refinement of the constituent
monomers in CNS [67]. A correct translation solution was then readily
obtained for both pentamers, using AMoRe [56] and BRUTE [57]. 
Manual inspection in XtalView [68] of the packing of the two pen-
tamers indicated space for two more pentamers in the asymmetric
unit. To find them, a ‘lock–washer’ GT3 pentamer model was created
by superimposing a monomer of the refined GT3–Pk-MCO complex
on the refined structure of the SLT-I B pentamer [40]. Again, ten sig-
nificant rotation function peaks were obtained, and pentamers corre-
sponding to the two unique orientations were subjected to rigid-body
refinement in CNS. Following this procedure, the translation for one
of the pentamers was clear from the output of AMoRe and BRUTE.
The correct translation solution for the fourth and final pentamer,
however,  could only be chosen among the top several possibilities by
inspecting the crystal packing using XtalView. The final molecular
replacement solution with the four pentamers resulted in an R factor
of 0.442 and an Rfree of 0.453 with data from 4–10 Å resolution. In
retrospect, it is not clear why the lock–washer model was required in
molecular replacement. Although pentamers 3 and 4 have larger
screw translations than pentamers 1 and 2 (Table 4), the systematic
screw component of the initial lock–washer model disappeared
during subsequent refinement.
Cross-validation data were selected in thin shells to reduce the propa-
gation of overfitting in this structure with high NCS. Rigid-body refine-
ment, first defining the four pentamers and then the 20 monomers as
rigid groups, was performed in CNS. Strict NCS refinement was then
performed followed by restrained NCS refinement in CNS using the
maximum-likelihood function MLI [63] and torsion-angle dynamics [69].
Intensity data were used in refinement, although all R factors reported
are in terms of structure-factor amplitudes. Refinement cycles were
combined with manual rebuilding using the program O [59] and 20-
fold NCS-averaged maps created by the DEMON package [60]. The
weight of the NCS term in the CNS energy function was gradually
reduced from 300 to 50 kcal mol–1 Å–2 during subsequent refinement
cycles. Water molecules were added and removed using a combina-
tion of ARP [70] with DEMON and CNS. The final R factor is 0.187 for
all data, and the Rfree is 0.232.
Accession numbers
The atomic coordinates and structure factors have been deposited with
the Protein Data Bank with accession codes 1QOH and 2BOS for the
native and complexed forms, respectively.
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